eISSN: 2345-2781  
Submitted: 03 Mar 2017

Accepted: 13 Oct 2018
First published online: 10 Jan 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract Page Views: 604
PDF Downloads: 440
Full Text Views: 0
J Renal Inj Prev. 2018;7(2):94-97.
doi: 10.15171/jrip.2018.22

Scopus id: 85044763901

Original

Does high-dose lovastatin therapy diminish the risk of iodinated contrast induced acute kidney injury? A double-blind placebo-controlled clinical trial

Mohammad Saad Forghani 1 * , Khaled Fathizade 1, Siamak Vahedi 2, Sara Ataei 3, Daem Roshani 4

1 Department of Internal Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
2 Department of Cardiology and, Kurdistan University of Medical Sciences, Sanandaj, Iran
3 Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
4 Department of Epidemiology and Biostatistics, Kurdistan University of Medical Sciences, Sanandaj, Iran
Corresponding author: Mohammad-Saad Forghani Email: m.s.forghani@muk.ac.ir

Abstract

Introduction: Contrast-induced acute kidney injury (CI-AKI) is one of the common causes of acute kidney injury. Various studies have been conducted to reduce the risk of CI-AKI.

Objectives: In this study, we examined the effectiveness of lovastatin in preventing CI-AKI in patients who required iodinated contrast injection.

Patients and Methods: This double-blind clinical trial was conducted on 122 patients scheduled for coronary angiography, abdominal computed tomography (CT) scan, and pulmonary CT angiography. Patients were randomly divided into two groups of receiving lovastatin and placebo. Estimated glomerular filtration rate (eGFR) at baseline and 48 hours after iodinated contrast injection was calculated.

Results: The incidence of CI-AKI in all study population was 3.3% (1.6% in lovastatin group, and 5% in placebo group; P = 0.309). A significant difference in the mean changes of eGFR (the differences in the mean of eGFR at the 48 hours after iodinated contrast injection versus baseline) between placebo and lovastatin group was observed (P < 0.001). This finding showed that, after intervention a further decline in the mean of eGFR in the placebo group than the lovastatin group was happened.

Conclusion: After iodinated contrast agent administration, in the lovastatin group mean change eGFR was significantly less than the placebo group. This finding indicated that highdose short-term lovastatin treatment may be effective on CI-AKI prevention.

Please cite this paper as: Forghani MS, Fathizade K, Vahedi S, Ataei S, Roshani D. Does high-dose lovastatin therapy diminish the risk of iodinated contrast induced acute kidney injury? A double-blind placebo-controlled clinical trial. J Renal Inj Prev. 2018;7(2):94-97. DOI: 10.15171/jrip.2018.22.
First name
 
Last name
 
Email address
 
Comments
 
Security code